Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

Nour Abuhadra, MD, discusses what the data from DESTINY-Breast04 means for trastuzumab deruxtecan in the triple-negative breast cancer space and future areas of research for antibody-drug conjugates in this disease.

Anthony Mato, MD, MSCE, discusses the relapsed refractory setting compared with the frontline setting and promising agents such as pirtobrutinib and zanubrutinib.

The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.

Ghassan K. Abou-Alfa, MD, discusses the administration of tremelimumab plus durvalumab in hepatocellular carcinoma and where the combination will fit in the treatment paradigm.

Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.

Alexander Drilon, MD, discusses key efficacy and safety data for selpercatinib from LIBRETTO-001, how the FDA approval of selpercatinib affects the current treatment landscape for RET fusion–positive advanced solid tumors, and ongoing research to expand the reach of tumor-agnostic drugs.

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Alexander Drilon, MD, discusses the significance of the FDA approval of selpercatinib in RET fusion–positive solid tumors.

Richard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.

Luis A. Diaz Jr, MD, is world renowned as a scientist and leader, but his greatest contribution to the world of cancer care might be as a collaborator and mentor.

Zachary Epstein-Peterson, MD, discusses pivotal clinical trials in the treatment of patients with mantle cell lymphoma.

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.

Steven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.

Zachary Epstein-Peterson, MD, discusses the importance of treatment sequencing decisions in mantle cell lymphoma.

Rona Yaeger, MD, discusses the unmet needs for patients with KRAS G12C–mutated colorectal cancer and the promising combination therapy of adagrasib and cetuximab.

The FDA has approved cobimetinib (Cotellic) for the treatment of adult patients with histiocytic neoplasms.

The novel brain-penetrant ROS1-selective inhibitor NVL-520 elicited clinical activity and was well tolerated in heavily pretreated patients with ROS1 fusion–positive non–small cell lung cancer.

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Single-agent neratinib produced robust responses in patients with metastatic or recurrent HER2-mutated cervical cancer, according to updated data from phase 2 SUMMIT basket trial.

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

Matthew J. Matasar, MD, discusses the unmet needs remaining in diffuse large B-cell lymphoma.

Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.